Biomarkers and Digital Technologies Transforming Oncology in Asia
Decision brief
Answer first · skim in under a minute
This article discusses the transformative role of biomarkers and digital technologies in oncology care in Asia, focusing on anticipated drug approvals by 2026.
Biomarkers and digital technologies are reshaping oncology across Asia in 2026 as sponsors pair broader molecular profiling with AI pathology and liquid biopsy programs, from TROP2-directed Phase 3 enrollment that includes Asian sites to multi-country cfDNA screening cohorts and new APAC diagnostic partnerships.
Contents10 sections
Key Takeaways
- TROPION-Lung17 is prospectively selecting TROP2 NMR–positive nonsquamous NSCLC patients with an AI companion device and will enroll sites in Asia, Europe, and North America.
- AstraZeneca and Roche Diagnostics Asia Pacific announced a May 18, 2026 MoU covering digital pathology training across nine Asian markets for breast and lung cancer biomarkers.
- SPOT-MAS real-world Asian data, following K-DETEK (NCT05227261), reported 68.1% PPV among workup-completed ctDNA-positive cases in 22,597 asymptomatic participants.
- Market-size forecasts vary by vendor and are not regulator-verified; operational decisions should follow trial protocols and labeled CDx pathways.
How are oncology biomarkers scaling beyond single companion tests in Asia?
Asia’s oncology pipeline increasingly needs panel and computational tests rather than one mutation–one drug kits. That shift shows up in ADC programs that require quantitative biomarker selection before randomization.
AstraZeneca and Daiichi Sankyo initiated TROPION-Lung17, a Phase 3 trial of DATROWAY versus docetaxel limited to TROP2 NMR–positive nonsquamous NSCLC, using Roche’s VENTANA TROP2 (EPR20043) RxDx Device. The trial plans about 400 patients across Asia, Europe, and North America.
What digital pathology moves are targeting Asia Pacific cancer care?
On May 18, 2026, AstraZeneca and Roche Diagnostics Asia Pacific announced a three-year MoU to accelerate AI-powered digital and computational pathology education and biomarker testing for breast and lung cancer in Singapore, Taiwan, Korea, Thailand, Malaysia, India, Indonesia, Vietnam, and the Philippines.
The PR Newswire APAC release cites Asia’s high share of global breast and lung cancer burden and notes access gaps such as Philippine oncologists reporting unavailable biomarker testing as a practice barrier.
What Asian evidence supports multi-cancer early detection liquid biopsies?
SPOT-MAS, a multimodal cfDNA assay spanning methylomic, fragmentomic, and genomic signals across 10 cancer types, reported real-world Asian performance in an ASCO 2026 abstract available via DOI 10.1200/jco.2026.44.19_suppl.14.
Among 22,597 asymptomatic participants with 12-month follow-up, 94 ctDNA-positive cases (0.42%) underwent workup; 64 malignancies or precancerous lesions were confirmed (PPV 68.1%), with sensitivity 79.0% and specificity 99.9%. The package builds on the prospective K-DETEK trial registered as NCT05227261.
Why do digital biomarkers matter between oncology visits?
Wearables and remote monitoring aim to catch chemotherapy toxicity between clinic visits, while computational pathology aims to standardize scoring of continuous biomarkers such as TROP2 or HER2-low that binary IHC can miss.
Those tools only change care when linked to a validated assay, a labeled therapy, and local laboratory capacity—exactly the gap the AstraZeneca–Roche training MoU tries to narrow across nine markets.
What should APAC oncology teams prioritize in 2026?
Priority one is assay access for decisions that already have labeled drugs: PD-L1, HER2, EGFR, ALK, and emerging ADC biomarkers. Priority two is participating in prospective biomarker-selected trials such as TROPION-Lung17 rather than assuming off-label AI scores.
Priority three is sober interpretation of MCED tests: high specificity still yields false positives that consume imaging and biopsy capacity in LMIC settings.
What remains unproven?
Vendor market forecasts for “Asia cancer biomarkers” or “digital biomarkers” are not FDA, EMA, or WHO datasets. TROPION-Lung17 has not reported Phase 3 outcomes. SPOT-MAS real-world PPV does not make MCED a replacement for national screening programs.
Delete any claim that Asia will uniformly adopt CGP or wearables by a fixed date without country-level reimbursement and laboratory evidence.
Related NovaPharma coverage
- Innovative Oncology Pharma Companies in China
- Asia Pacific eClinical Solutions Market Report
- Innovent–Pfizer Cancer Drug Deal
Frequently Asked Questions
How are biomarkers changing oncology care in Asia?
Asia oncology programs are moving beyond one-drug companion tests toward broader profiling and AI-assisted pathology, illustrated by TROP2 computational scoring in global Phase 3 NSCLC trials that enroll Asian sites and by large Asian cfDNA multi-cancer early detection cohorts.
What digital pathology partnerships are active in Asia Pacific oncology?
In May 2026, AstraZeneca and Roche Diagnostics Asia Pacific announced a three-year memorandum of understanding to advance AI-powered digital pathology education and biomarker testing for breast and lung cancer across nine Asia markets.
What real-world Asian data exist for multi-cancer early detection?
ASCO abstract data for SPOT-MAS, building on the K-DETEK trial (NCT05227261), reported real-world performance in more than 22,000 asymptomatic participants with a positive predictive value of 68.1% among ctDNA-positive cases completing workup.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…